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Abstract
Background: Wingspan stenting for the treatment of complex intracranial atherosclerotic stenosis (ICAS), i.e., that
involving tortuous vascular pathways, long (>15 mm) lesions or arterial bifurcations, has a relatively high risk of
complications. This retrospective study assessed the safety and efficacy of undersized balloon angioplasty followed
by deployment of the more flexible Enterprise stent for the treatment of complex symptomatic ICAS.
Methods: Forty-four patients on combined antiplatelet therapy and intensive risk factor management and a
symptomatic 70–99 % stenosis of a major intracranial artery in complex settings that was treated with balloon angioplasty
and Enterprise stent deployment between July 2009 and August 2013 were enrolled. Primary outcome was occurrence of
ischemic or hemorrhagic stroke or death within 30 days after intervention. Secondary outcomes included procedural
success (defined as achievement of <50 % immediate residual stenosis), and follow-up clinical and angiographic
outcomes.
Results: With a procedural success rate of 100 %, stenosis was reduced from 79.3 ± 8.1–14.9 ± 12.3 %. Three (6.8 %)
ischemic and 1 (2.2 %) hemorrhagic strokes occurred during the periprocedural period, with no further transient
ischemic attacks or strokes in the 42 patients available at median 25.6 (range, 12–57) months follow-up. Of the 38
(86.4 %) patients who underwent angiographic follow-up, 3 (6.81 %) developed >50 % in-stent restenosis after mean
22 months follow-up.
Conclusion: In this retrospective, single-center experience, undersized balloon angioplasty followed by Enterprise
stent deployment appears technically feasible with a relatively low rate of complications for the treatment of complex
symptomatic ICAS. Prospective, multicenter, randomized controlled trials against optimal medical management are
warranted.
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Background
Approximately 5–10 % of all strokes and transient ische-
mic attacks (TIAs) are secondary to intracranial athero-
sclerotic disease (ICAD), whose incidence varies by race
being more prevalent among Chinese, Japanese, African-
Americans, and Hispanics [1, 2]. Although endovascular
treatment emerged in the 1980s as a potential option for
intracranial atherosclerotic stenosis (ICAS) with promising
results upon device development and improvement [3, 4],
its superiority to optimal medical treatment remains con-
troversial [5]. In SAMMPRIS, the only randomized con-
trolled trial (RCT) comparing the Wingspan stent and
optimal drug therapy, Wingspan stent use was associated
with a higher rate of perioperative complications [6]. Com-
plex ICAS, i.e., that in tortuous vascular segments, long
(>15 mm) lesions and/or arterial bifurcations, has been as-
sociated with higher rates of complications and renders
particularly difficult the deployment of the Wingspan
stent because of its high radial force and rigidity [7, 8].
The self-expanding, closed-cell Enterprise stent, which
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was originally designed for neck remodeling in the treat-
ment of wide-necked intracranial aneurysms [9], appears
better suited than the Wingspan stent for the treatment of
complex ICAS because of its high flexibility, special carrier
system structure [10] and reduced radial force [10], which
is nonetheless sufficient to prevent elastic recoil and
restenosis. In the study by Henkes et al. [11], treatment of
intracranial atherosclerotic arterial stenosis with the En-
terprise stent yielded a relatively lower in-stent restenosis
rate than with the Wingspan stent; however, reperfusion
hemorrhage and plaque shift in high-grade (>70 %) sten-
oses remained concerns. This paper reports the long-term
safety and efficacy results of our single-center experience
since we began in 2009 to use balloon dilatation and En-
terprise stent deployment exclusively for the treatment of
complex severe ICAS.
Methods
Written informed consent was obtained from all partici-
pants. In addition, our local institutional ethics review
board (the Medical Ethics Committee of Second Military
Medical University) approved the research protocol for
the retrospective study. Participants of the current study
also agreed with publication of their personal informa-
tion for research purposes.
Patient population
From July 2009 to August 2013, 357 patients whose CTA/
MRA confirmed severe stenosis (>70 %) were admitted to
our department for further diagnostic cerebral angiog-
raphy. Among them, 298 patients demonstrated severe
stenosis (>70 %) and were treated by percutaneous translu-
minal angioplasty and stenting (PTAS: 34 with the Solitaire
stent; 137 with the Wingspan stent; and 83 with domestic
stents). Of the 298 patients, 44 patients were treated with
the Enterprise stent and met the following inclusion
criteria: (1) stenosis >70 % as determined by digital sub-
traction angiography (DSA) using the formulas described
by the Warfarin Aspirin Symptomatic Intracranial Dis-
ease (WASID) method; (2) recurrent low-flow TIAs or
non-disabling ischemic stroke despite antiplatelet or
anticoagulation therapy (at our center, patients with
symptomatic ICAS undergo close outpatient follow-up
and aggressive medical management according to the
guidelines for the prevention of stroke in patients with
stroke and TIA); and (3) stenoses located in lesions that
are long, at a bifurcation, and/or with tortuous access,
and therefore particularly challenging for Wingspan
stent use because of its rigidity. Patients with any of the
following were excluded: (1) total occlusive lesion; (2)
severe disability because of stroke or dementia; or (3)
inability to give informed consent.
Lesion characteristics
All patients underwent cerebral angiography to confirm
the diagnosis, and three-dimensional reconstruction was
performed to accurately measure the morphology and ac-
cess of the targeted segment of stenosis. The measurement
of normal and stenotic vessel diameter was performed
using the two-dimensional angiographic image with the
help of a measuring ball, and the degree of stenosis was
calculated with the formulas described by the WASID
method [12]. We used the LMA classification [13] that
Jiang et al. described to identify the location, morphology,
and access of intracranial stenosis. Among the 44 lesions
studied, 24 were located in the middle cerebral artery, one
in the anterior cerebral artery, 8 in the intracerebral verte-
bral artery (VA), and 11 in the basilar artery trunk. The
average vascular lesion length was 11.64 ± 6.33 mm (range,
4.20–28.00), and the mean reference artery diameter was
2.63 ± 0.79 mm (range, 1.52–4.01). Stenosis was located
adjacent to bifurcations in 28 (63.6 %) patients.
Procedures
A dose of 300 mg of acetylsalicylic acid (ASA) and 75 mg
of Clopidogrel was given at least 3 days before endovascu-
lar treatment, which was always performed under general
anesthesia. A 6 F guiding catheter was introduced through
a femoral sheath. During intervention, patients were hepa-
rinized to a doubled activated clotting time. A radiologic
examination of the target vessel was performed using a
biplane angiographic system (Artis zee Biplane; Siemens,
Erlangen, Germany) or a single-arm angiosuite (Philips
FD, Netherlands). Rotational angiography followed by 3D
reconstruction was performed to understand the normal
vessel diameter adjacent to the stenosis and the diameter
and the length of the stenosis. The enhanced Dyna CT
was also performed to access the location of the plaque
and the relationship between the stenosis and important
vessel branches. Under a road-map, the vessel distal to the
stenosis was catheterized with Transcend Floppy microgui-
dewire (Boston, Scientific), followed by predilatation with a
balloon (Gateway, Stryker). After deflation and withdrawal
of the balloon catheter, a flushed 0.021-inch microcatheter
(Prowler Select Plus, Codman) was navigated over the
exchange-wire. The Enterprise stent (Codman) was de-
ployed to cover the targeted stenosis. A daily dose of as-
pirin (300 mg) and clopidogrel (75 mg) was recommended
for 6 weeks after discharge followed by only aspirin. We
did not perform routine response testing for aspirin or clo-
pidogrel mainly because of cost and coverage constraints.
Treatment for hypertension, and to normalize blood glu-
cose and lipid levels if needed was also suggested. All
patients received statin therapy after stenting, 30 (68.1 %)
patients with hypertension were treated with antihyperten-
sive drugs, and 13 (29.5 %) patients with diabetes mellitus
received either metformin or insulin therapy.
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Evaluation of outcomes and clinical and angiographic
follow-up
The primary outcome for this study was occurrence of
any stroke or death during/after the procedure and at
30-day follow-up. Secondary outcomes were procedural
success, occurrence of >50 % in-stent restenosis con-
firmed by DSA, and occurrence of transient ischemic at-
tack (TIA) or stroke attributable to the target vessel
during the follow-up observation period.
Procedural success was defined as accurate delivery
and deployment of the stent (in all intended stenting
procedures), covering the target lesion completely and
resulting in a residual stenosis of less than 50 %.
The neurological status was documented according to
the National Institute of Health Stroke Scale (NIHSS)
score at discharge. A TIA was defined as neurological
worsening with complete recovery within 24 h. Minor
and major stroke was defined as persistent worsening of
the NIHSS score of <4 or ≥ 4 points, respectively. We
defined symptomatic brain hemorrhage as parenchymal,
subarachnoid, or intraventricular hemorrhage detected
by CT or MRI that was associated with new neurological
signs or symptoms lasting 24 h or more or a seizure.
The initial and follow-up clinical evaluations were per-
formed by two neurologists (P Zhang and L Chen).
Angiographic follow-up was scheduled at 3 and 6 months
and yearly thereafter with DSA, CTA, and/or CTA/CTP.
DSA was routinely used to assess restenosis, and although
image might be affected by stent-related artifacts, CTA was
used when patients refused invasive assessment. ISR was
defined as >50 % stenosis within or immediately adjacent
(within 5 mm) to the implanted stent with >20 % absolute
luminal loss in 2D-DSA image.
Statistical methods
Statistical analyses were performed using SAS 9.1 (SAS
Institute Inc., Cary, NC). Mean, median, and standard
deviation were used for descriptive statistics. Differences
between before and after treatment were analyzed using
the t- and chi-square tests for parametric and nonpara-




The study cohort included 44 patients (32 men and 12
women) with a mean age of 60.45 ± 9.07 years (range
36–78 years). All patients presented with an ischemic
stroke (26 patients, 59.09 %) or TIA (18 patients,
40.91 %) in the territory of a suspected 70–99 % stenotic
intracranial artery. Distal ischemia was present in 12 pa-
tients, and hemodynamic compromise in 32 patients;
there were no cases of perforator stroke, which might
have increased procedural risk. The stenting procedure
was performed 43.40 ± 10.37 days (range 9–67 days)
from the qualifying event. The general characteristics of
the included patients are summarized in Table 1.
Lesion and angiographic characteristics
All 44 patients underwent digital subtraction angiography
(DSA) preoperatively. The degree of stenosis was deter-
mined by using the formulas described by the WASID
method. The distal artery diameter was defined as the ref-
erence artery diameter. Lesion classification was according
to the morphology and access criteria system, as described
by Jiang et al. The lesion characteristics are summarized
in Table 2.
Procedural results and periprocedural complications
The overall procedural success rate was 100 %. The average
degree of target stenosis before treatment, after balloon
dilatation and after stent deployment was determined as
79.3 ± 8.1, 23.4 ± 9.5 % and 14.9 ± 12.3 %, respectively.
Table 1 Demographic and clinical characteristics of the 44
patients treated with Enterprise stents for complex symptomatic
intracranial stenosis
N (%)
Age, years 60.45 ± 9.07
Male gender 32 (72.73)
Symptoms





Diabetes mellitus 13 (29.55)
Coronary artery disease 2 (4.55)
Body mass index
18.5–23.9 16 (36.36)
24 ~ 27.9 24 (54.55)
≥28 4 (9.09)




Time intervals from last event to intervention, day
<30 11 (25.00)
≥30 33 (75.00)
Symptom pattern unstable/stable 1/43
Note: TIA transient ischemic attack, Symptom pattern unstable indicates
resolved, improving or unchanging symptoms before the stent placement
procedure; unstable indicates progressive or fluctuating neurologic symptoms
(National Institutes of Health Stroke Scale score > 4) corresponding to
intracranial stenosis within the 2 days prior to the stent placement procedure
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Thirty-day follow-up was available for all 44 patients.
Major procedure-related complications (stroke or
death) during the periprocedural period (30 days) were
encountered in 4 (9.1 %) cases. Three patients devel-
oped a new emerging ischemic stroke that was classi-
fied as a perforator event, including two upper basilar
trunks and one M1 segment. One patient experienced
intraparenchymal hemorrhage due to hyperperfusion
injury. At our department, blood pressure is strictly
controlled after intervention in all patients to avoid
hyperperfusion injury. Two patients developed groin
hematoma after the procedure and recovered after
hemostasis by compression; one patient developed
pneumonia because he was bedridden. The lesion char-
acteristics of the latter four patients who suffered com-
plications are summarized in Table 3. No patient
suffered myocardial infarction, gastrointestinal bleeding,
or died during the periprocedural period.
Clinical and angiographic follow-up results
A clinical evaluation was performed in all patients at dis-
charge using the National Institute of Health Stroke Scale
(NIHSS) score. The NIHSS score at discharge was 0 in 25
patients, one in 17 patients and two in 2 patients.
A total of 44 patients were available for a clinical follow-
up visit 12–57 months (median 25.6 months) after treat-
ment. Thirty-one patients had their follow-up visit more
than 24 months after intervention (Fig. 1). No patient
experienced recurrent TIA or stroke or died. Overall, 38
patients (86.3 %) underwent DSA follow-up examinations
and another 6 patients underwent CT angiography during
the follow-up period. The median angiographic follow-up
period was 11.5 months (6–30.2 months). Three patients
(6.8 %) developed ISR, defined as an in-stent stenotic
lesion of more than 50 % on the follow-up DSA series,
after an average follow-up of 22 months. The lesion char-
acteristics of the three patients who developed ISR are
summarized in Table 4. One (2.3 %) of these recurrent le-
sions received balloon angioplasty (Pre/Post retreatment
stenosis, 80/30 %) (Fig. 2).
Discussion
In this retrospective single-center study, undersized bal-
loon angioplasty followed by stenting with the Enterprise
stent appeared safe and effective in treating complex
symptomatic ICAS, i.e., that in tortuous vascular seg-
ments, long lesions or bifurcations which render challen-
ging deployment of the Wingspan stent and are associated
with higher periprocedural risk rates. Use of the Enterpise
stent in the latter setting was associated with a higher
Table 2 Lesion characteristics for the 44 patients treated with
Enterprise stents for complex symptomatic intracranial stenosis
Characteristics N (%)
Location (i)
Anterior circulation 25 (56.82)











Mean stenosis degree, % 70–92 (mean, 79.32 ± 8.18)
Vascular lesion length, mm 4.20–28.00 (mean, 11.64 ± 6.33)









Note: MCA middle cerebral artery, ACA anterior cerebral artery, PCA posterior
cerebral artery, VA vertebral artery, BA basilar artery, Classification was
according to the morphology and access criteria system
















1 MCA T/A, C, II 1.5/9 4.5/28 90/40 3 h Infarction Decreased muscle
strength
2
2 MCA B/B, B, II 2.25/9 4.5/22 90/0 5 h ICH Hemiplegia 2
3 BA T/N, C, I 1.5/9 4.5/22 75/0 40 h Infarction Visual field defects 1
4 BA T/N, C, II 1.5/15 4.5/22 70/20 40 h Infarction Decreased muscle
strength
1
Record of LMA classification. Situation: origin (O) or trunk (T) or bifurcation (B)/location, morphology, access classification. ICH intracranial hemorrhage
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procedural success rate (100 %), lower rate of complica-
tions (perioperative stroke incidence, 9.1 %) and better
long-term outcome (ISR rate, 6.8 %) than published results
for the Wingspan stent.
The best treatment option for symptomatic intra-
cranial atherosclerotic stenosis remains controversial
[14, 15]. Results from WASID and SAMPPRIS studies
suggested that optimal medical therapy may reduce the
recurrence rate of stroke [6, 16]. Intracranial stents are
also thought to minimize stroke recurrence by improving
blood flow, especially for severe stenosis with serious hy-
poperfusion [17, 18]. Since 2000, many studies have
reported the safety and efficacy of stenting for ICAD.
Wingspan is currently the only self-expanding stent ap-
proved by FDA for ICAD treatment. Many single- and
multicenter clinical studies have proven that stenting for
ICAD is relatively safe, however, in the multicenter, ran-
domized controlled SAMMPRIS trial, optimized medical
therapy was superior to stenting combined with medical
treatment in prevention of stroke for patients with ICAD.
Possible explanations for the higher periprocedural event
rate in SAMMPRIS than in previous registries include
higher stenosis severity and earlier treatment in SAMM-
PRIS (within 30 days of the qualifying event) [11, 19]. The
design characteristics of the Wingspan stent also increased
procedural difficulties and risks, particularly in tortuous
vascular pathways, longer-segment lesions or cases involv-
ing arterial bifurcation [20–22]. The LMA classification
seems to be helpful in informing individual therapy and
predicting stenting results. In cases with tortuous access
pathways, it became difficult and dangerous to superselect
or navigate the Wingspan system to the target the stenosis
segment. Jiang and his colleagues reported a mortality rate
of 0, 0, and 25 % for types A, B, and C lesions, respectively
[13]. In this study, 21 patients (47.7 %) and 19 patients
(43.1 %) were classified with type B and C morphology, re-
spectively. All procedures were performed successfully
without fatalities. According to LMA classification, 17
(38.6 %) and 5 (11.3 %) patients were classified as type II
and III, respectively, by access. The high procedural success
rate might be related with the design of the stent delivery
system. The Enterprise self-expanding nitinol stent was ori-
ginally developed for neck remodeling in the treatment of
wide-necked intracranial aneurysms. The stent is intro-
duced through a standard 0.021-inch inside diameter
microcatheter and can be partially deployed as much as
70 % within the artery with the possibility of recapturing
and redeployment if needed [23].
In a previous study, Henkes and his colleagues demon-
strated that undersized balloon angioplasty and deploy-
ment of an Enterprise stent is safe and effective for
intracranial stenosis, resulting in a rate of major complica-
tion of 7.7 % within 30 days post procedure. Several
authors also investigated the safety and feasibility of drug-
eluting stent placement for ICAD [24, 25], and albeit
yielding better long-term patency rate, they are frequently
Fig. 1 A 41-year-old man with a severe stenosis of the M1 segment of the left middle cerebral artery (MCA) was referred for evaluation of stroke.
Diagnostic cerebral angiography confirmed a preocclusive (>80 %) stenosis of the left MCA a. The patient underwent percutaneous transluminal
angioplasty and Enterprise stent placement. The subtracted image demonstrates near 30 % postprocedural residual stenosis b. The DynaCT scan shows
the morphology of the stent after placement c. The 11 months follow-up angiogram shows complete patency of the stented segment d and good
outcome at 30 months follow-up as confirmed by CTA e





















1 MCA B/C, B, II 7.22 2/15 5.0 4.5/22 70/10 29 55 Decreased
muscle strength
No






3 BA T/N, B, I 9.75 2.5/15 5.0 4.5/15 90/30 7 70 None No
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too stiff to access distal stenosis lesions which might result
in a penetration event. Although a relatively higher rate of
periprocedural complications was observed in the present
study, it may be related to the high grade of stenosis
(>70 %) and the complicated stenosis lesions treated in the
selected patients.
Atherosclerotic stenosis often involves the origin of a
major artery [26]. In this study, the incidence of lesions in-
volving bifurcation or ostium was 63.6 % (28/44). Balloon
angioplasty or stenting may result in occlusion of branches
due to the atheromatous components squashed into the
origin of branches, especially in patients with type D, C,
and F locations according to LMA classification, resulting
in subsequent infarction. Thus, preprocedural evaluation
such as wall imaging of targeted stenosis becomes neces-
sary. Three of the complications of ischemic stroke that
occurred in our study were related to occlusion of perfor-
ating arteries.
A high rate of ISR is the major limitation of intracra-
nial angioplasty. The ISR rate of Wingspan procedures
was reported to range between 7.5 % and 31.2 % [27].
Several factors may contribute to ISR, such as stent
thrombogenicity, vascular injury by balloon dilatation,
inflammatory reactions of the vessel wall, stent radial
force, lesion length, as well as uncontrollable diabetes.
Compared with Wingspan, the Enterprise stent exerts
less radial force [10], and Zsolt et al. reported satisfac-
tory ISR rates with the Enterprise stent (24.7 % resten-
osis during a mean 6.9 months of follow-up) compared
with Wingspan stent [4]. In the present study, 3 (6.8 %)
patients suffered ISR proved by DSA examination, two
of whom received further intervention.
The present study has limitations inherent to its
retrospective design and relatively small sample size for
a 4-year enrollment period, which likely introduce se-
lection bias. Prospective, multicenter, randomized con-
trolled trials with longer-term follow-up and larger
sample size are warranted.
Conclusions
This is a case series study of ICAS treated by Enterprise
stent placement. Deployment of an Enterprise stent with
Fig. 2 A 39-year-old man with a severe stenosis of the M1 segment of the left middle cerebral artery (MCA) was referred for evaluation of stroke.
Diagnostic cerebral angiography confirmed a preocclusive (90 %) stenosis of the left MCA a. The patient underwent percutaneous transluminal angioplasty
and Enterprise stent placement. The subtracted image demonstrates near 30 % postprocedural residual stenosis b. After 4 months, the patient experienced
TIAs in the dependent territory, and follow-up angiography revealed in-stent restenosis (80 %) and diffuse intimal hyperplasia throughout the entire
stented segment d. Angioplasty was performed with a slow, graded inflation of the balloon (Gateway, 1.5/9) to a pressure of 7 atm e. The subtracted
image post retreatment demonstrates near 30 % residual stenosis f
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undersized balloon angioplasty in the treatment of
symptomatic intracranial atherosclerotic stenosis appears
safe and effective, with a high technical success rate,
relatively low periprocedural complication rate, and fa-
vorable outcome during follow-up.
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